FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF	CHANGES	IN RENEFIC	CIAI (OWNERSHIP
	∙.		DEILE I	JI//L \	511 11 - 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burd	len								
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Gross Jane A</u>					2. Issuer Name and Ticker or Trading Symbol Aptevo Therapeutics Inc. [APVO]									onship of Reporting Perso all applicable) Director		10% Owner		
(Last) (First) (Middle) 2401 4TH AVENUE, SUITE 1050						Date 6	of Earliest	t Transa	ction (Mo	onth/C	ay/Year)		V Officer below)	Officer (give title below) See Remarks Other (s below)		pecify		
(Street) SEATTL	LE W	/A	98121		_ 4 .	If Ame	endment,	Date of	Original I	Filed	(Month/Day	/Year)	Line	Form fi	led by One	Repo	(Check App rting Persor One Report	.
(City)	(S	state)	(Zip)											Person				
Table I - Non-Deriv 1. Title of Security (Instr. 3) 2. Transa Date (Month/L				nsactio	tion 2A. Deemed Execution Date,			3. Transaction Code (Instr. 8) 4. Securities Acquired (A) (Disposed Of (D) (Instr. 3, 4)				d (A) or	5. Amount of		Form: Direct		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
									Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			,msu. 4 <i>j</i>
Common	Stock			03/0	09/20	9/2018			M		9,728	A	(1)	105	,437	D		
Common Stock			03/0	09/20	9/2018		F		2,282 D		\$3.13	3 103	103,155		D			
			Table II -								osed of, onvertib			Owned				
1. Title of Derivative Security (Instr. 3)	Conversion Date or Exercise (Month/Day/Year) i		if any	cecution Date, Tr		ction Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisal Expiration Date (Month/Day/Year		of Securitie		ties ig e Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	on(s)		
Employee Stock Options (Right to Buy)	\$3.13	03/09/2018			A		67,400		(2)		03/09/2028	Common Stock	67,400	\$0	67,40	0	D	
Restricted	(1)	03/09/2018			М			9,728	(3)		(3)	Common	9,728	\$0	9,138	3	D	

Explanation of Responses:

- 1. Each RSU converts into the Issuer's common stock on a one-for-one basis.
- 2. On March 9, 2018, the reporting person was granted 67,400 stock options vesting in three equal annual installments beginning on the first anniversary of the grant date.
- 3. The RSUs were originally issued by Emergent BioSolutions, Inc. ("Emergent") on March 10, 2015. As a result of the spin-off of the Issuer from Emergent effective on August 1, 2016, each RSU was adjusted and assumed by the Issuer. The RSUs fully vested as of March 9, 2018.

Remarks:

Title - SVP, Research and Non-Clinical Development

/s/ Benjamin J. Stein, attorneyin-fact

03/13/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.